Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00245141|
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : October 27, 2005
Last Update Posted : August 12, 2013
RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vincristine, dactinomycin, and cyclophosphamide together with or without radiation therapy works in treating patients with embryonal rhabdomyosarcoma.
|Condition or disease||Intervention/treatment||Phase|
|Sarcoma||Biological: dactinomycin Drug: cyclophosphamide Drug: vincristine sulfate Radiation: radiation therapy||Phase 2|
- Determine the progression-free survival rate in patients with low-risk embryonal rhadomyosarcoma treated with a shortened treatment schedule of vincristine, dactinomycin, and cyclophosphamide with or without radiotherapy.
OUTLINE: Patients receive vincristine IV, dactinomycin IV, and cyclophosphamide IV. Patients may also undergo radiotherapy. Treatment repeats every 3 weeks for up to 8 courses (total of 24 weeks) in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma|
|Study Start Date :||May 2004|
|Estimated Primary Completion Date :||April 2011|
- Disease-free survival as measured by Kaplan-Meier method 3 years after study entry
- Overall survival as measured by Kaplan-Meier method 3 years after study entry
- Progression-free survival as measured by Kaplan-Meier method during events
- Complete response rate (orbit, group III only) at completion of study treatment
- Rate of toxicity as measured by NCI-CTC v 2.0 3 years after study entry
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245141
Show 51 Study Locations
|Study Chair:||Hajime Hosoi||Kyoto Prefectural University of Medicine|
|OverallOfficial:||Masa-aki Kumagai, MD||National Center for Child Health and Development|